nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—adrenal gland cancer	0.848	1	CbGaD
Paroxetine—SLC6A2—sympathetic nervous system—adrenal gland cancer	0.00864	0.225	CbGeAlD
Paroxetine—HTR2A—sympathetic nervous system—adrenal gland cancer	0.00519	0.135	CbGeAlD
Paroxetine—HTR2A—vein—adrenal gland cancer	0.00486	0.127	CbGeAlD
Paroxetine—CYP2C9—urine—adrenal gland cancer	0.00345	0.09	CbGeAlD
Paroxetine—HTR2A—urine—adrenal gland cancer	0.00285	0.0741	CbGeAlD
Paroxetine—CYP2D6—urine—adrenal gland cancer	0.00259	0.0675	CbGeAlD
Paroxetine—TACR1—adrenal gland—adrenal gland cancer	0.00223	0.0581	CbGeAlD
Paroxetine—SLC6A2—gonad—adrenal gland cancer	0.00104	0.0271	CbGeAlD
Paroxetine—CYP2B6—adrenal cortex—adrenal gland cancer	0.000924	0.0241	CbGeAlD
Paroxetine—SLC6A2—adrenal gland—adrenal gland cancer	0.000905	0.0236	CbGeAlD
Paroxetine—CYP2C8—pituitary gland—adrenal gland cancer	0.000832	0.0217	CbGeAlD
Paroxetine—CYP2B6—gonad—adrenal gland cancer	0.000765	0.0199	CbGeAlD
Paroxetine—CYP2B6—adrenal gland—adrenal gland cancer	0.000667	0.0174	CbGeAlD
Paroxetine—HTR2A—gonad—adrenal gland cancer	0.000624	0.0163	CbGeAlD
Paroxetine—HTR2A—pituitary gland—adrenal gland cancer	0.000609	0.0159	CbGeAlD
Paroxetine—HTR2A—adrenal gland—adrenal gland cancer	0.000544	0.0142	CbGeAlD
Paroxetine—ABCB1—adrenal cortex—adrenal gland cancer	0.000494	0.0129	CbGeAlD
Paroxetine—ABCB1—gonad—adrenal gland cancer	0.000409	0.0107	CbGeAlD
Paroxetine—ABCB1—pituitary gland—adrenal gland cancer	0.000399	0.0104	CbGeAlD
Paroxetine—ABCB1—adrenal gland—adrenal gland cancer	0.000357	0.00929	CbGeAlD
Paroxetine—CHRM2—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000109	0.000958	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.000109	0.000958	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—POMC—adrenal gland cancer	0.000108	0.000956	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IGF1R—adrenal gland cancer	0.000108	0.000954	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000106	0.000938	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SDHB—adrenal gland cancer	0.000105	0.000926	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000103	0.000912	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000103	0.000907	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—adrenal gland cancer	0.000103	0.000905	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000102	0.000904	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—adrenal gland cancer	0.000102	0.000902	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	0.000102	0.0009	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000102	0.000899	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000101	0.000895	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—adrenal gland cancer	0.000101	0.000893	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000101	0.000888	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—TSHR—adrenal gland cancer	0.0001	0.000886	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.0001	0.000884	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—TSHR—adrenal gland cancer	9.99e-05	0.000882	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	9.98e-05	0.000881	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—TSHR—adrenal gland cancer	9.96e-05	0.000879	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CDC42—adrenal gland cancer	9.94e-05	0.000876	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	9.89e-05	0.000872	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—TSHR—adrenal gland cancer	9.87e-05	0.00087	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNRH1—adrenal gland cancer	9.82e-05	0.000867	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ZNRF3—adrenal gland cancer	9.72e-05	0.000857	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ZNRF3—adrenal gland cancer	9.66e-05	0.000853	CbGpPWpGaD
Paroxetine—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	9.64e-05	0.00085	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ZNRF3—adrenal gland cancer	9.63e-05	0.00085	CbGpPWpGaD
Paroxetine—CYP2C9—Biological oxidations—POMC—adrenal gland cancer	9.55e-05	0.000843	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ZNRF3—adrenal gland cancer	9.54e-05	0.000842	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CDC42—adrenal gland cancer	9.52e-05	0.000839	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—GNAS—adrenal gland cancer	9.49e-05	0.000837	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNRH1—adrenal gland cancer	9.41e-05	0.00083	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TERT—adrenal gland cancer	9.31e-05	0.000821	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SDHD—adrenal gland cancer	9.29e-05	0.000819	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—RRM1—adrenal gland cancer	9.29e-05	0.000819	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	9.22e-05	0.000813	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SDHB—adrenal gland cancer	9.14e-05	0.000807	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GNAS—adrenal gland cancer	9.09e-05	0.000802	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CDC42—adrenal gland cancer	9.02e-05	0.000796	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SPRY2—adrenal gland cancer	8.98e-05	0.000793	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TSHR—adrenal gland cancer	8.76e-05	0.000772	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CDC42—adrenal gland cancer	8.64e-05	0.000762	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GNAS—adrenal gland cancer	8.62e-05	0.000761	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SDHB—adrenal gland cancer	8.62e-05	0.00076	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SPRY2—adrenal gland cancer	8.6e-05	0.000759	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SDHB—adrenal gland cancer	8.54e-05	0.000754	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TSHR—adrenal gland cancer	8.38e-05	0.00074	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	8.26e-05	0.000729	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GNAS—adrenal gland cancer	8.26e-05	0.000728	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MEN1—adrenal gland cancer	8.23e-05	0.000726	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—BAD—adrenal gland cancer	8.1e-05	0.000715	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—RRM1—adrenal gland cancer	7.99e-05	0.000705	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SDHD—adrenal gland cancer	7.99e-05	0.000705	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MEN1—adrenal gland cancer	7.88e-05	0.000695	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	7.69e-05	0.000678	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—POMC—adrenal gland cancer	7.67e-05	0.000676	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	7.65e-05	0.000675	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—POMC—adrenal gland cancer	7.63e-05	0.000673	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	7.62e-05	0.000672	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—POMC—adrenal gland cancer	7.6e-05	0.000671	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—POMC—adrenal gland cancer	7.53e-05	0.000664	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	7.5e-05	0.000662	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—POMC—adrenal gland cancer	7.47e-05	0.000659	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—BRAF—adrenal gland cancer	7.38e-05	0.000651	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PRKACA—adrenal gland cancer	7.21e-05	0.000636	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PRKACA—adrenal gland cancer	7.17e-05	0.000633	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PRKACA—adrenal gland cancer	7.15e-05	0.000631	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—EGFR—adrenal gland cancer	7.15e-05	0.000631	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PRKACA—adrenal gland cancer	7.08e-05	0.000625	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MED12—adrenal gland cancer	6.92e-05	0.000611	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	6.84e-05	0.000604	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—adrenal gland cancer	6.78e-05	0.000598	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—RRM1—adrenal gland cancer	6.76e-05	0.000597	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SDHD—adrenal gland cancer	6.76e-05	0.000597	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CDC42—adrenal gland cancer	6.74e-05	0.000594	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	6.72e-05	0.000593	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	6.71e-05	0.000592	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CDC42—adrenal gland cancer	6.7e-05	0.000591	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CDC42—adrenal gland cancer	6.68e-05	0.000589	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNRH1—adrenal gland cancer	6.66e-05	0.000587	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNRH1—adrenal gland cancer	6.62e-05	0.000584	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CDC42—adrenal gland cancer	6.61e-05	0.000583	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNRH1—adrenal gland cancer	6.6e-05	0.000582	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNRH1—adrenal gland cancer	6.54e-05	0.000577	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GNAS—adrenal gland cancer	6.44e-05	0.000568	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GNAS—adrenal gland cancer	6.4e-05	0.000565	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—POMC—adrenal gland cancer	6.39e-05	0.000564	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GNAS—adrenal gland cancer	6.38e-05	0.000563	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GNAS—adrenal gland cancer	6.32e-05	0.000557	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PRKACA—adrenal gland cancer	6.28e-05	0.000554	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—POMC—adrenal gland cancer	6.12e-05	0.00054	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CDC42—adrenal gland cancer	6.12e-05	0.00054	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SPRY2—adrenal gland cancer	6.09e-05	0.000537	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CDC42—adrenal gland cancer	6.08e-05	0.000537	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CDC42—adrenal gland cancer	6.06e-05	0.000535	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SPRY2—adrenal gland cancer	6.06e-05	0.000534	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SPRY2—adrenal gland cancer	6.04e-05	0.000533	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PRKACA—adrenal gland cancer	6.02e-05	0.000531	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CDC42—adrenal gland cancer	6.01e-05	0.00053	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SPRY2—adrenal gland cancer	5.98e-05	0.000528	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MED12—adrenal gland cancer	5.96e-05	0.000525	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TSHR—adrenal gland cancer	5.94e-05	0.000524	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TSHR—adrenal gland cancer	5.9e-05	0.000521	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—RRM1—adrenal gland cancer	5.89e-05	0.00052	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SDHD—adrenal gland cancer	5.89e-05	0.00052	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TSHR—adrenal gland cancer	5.89e-05	0.000519	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GNAS—adrenal gland cancer	5.84e-05	0.000516	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TSHR—adrenal gland cancer	5.83e-05	0.000514	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GNAS—adrenal gland cancer	5.81e-05	0.000513	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—POMC—adrenal gland cancer	5.81e-05	0.000512	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GNAS—adrenal gland cancer	5.79e-05	0.000511	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GNAS—adrenal gland cancer	5.74e-05	0.000506	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MEN1—adrenal gland cancer	5.58e-05	0.000492	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—POMC—adrenal gland cancer	5.56e-05	0.00049	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RRM1—adrenal gland cancer	5.55e-05	0.00049	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SDHD—adrenal gland cancer	5.55e-05	0.00049	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MEN1—adrenal gland cancer	5.55e-05	0.00049	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	5.55e-05	0.000489	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MEN1—adrenal gland cancer	5.53e-05	0.000488	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RRM1—adrenal gland cancer	5.5e-05	0.000486	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SDHD—adrenal gland cancer	5.5e-05	0.000486	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MEN1—adrenal gland cancer	5.48e-05	0.000483	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDC42—adrenal gland cancer	5.33e-05	0.00047	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CTNNB1—adrenal gland cancer	5.33e-05	0.00047	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	5.32e-05	0.000469	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF2—adrenal gland cancer	5.14e-05	0.000453	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDC42—adrenal gland cancer	5.1e-05	0.00045	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNAS—adrenal gland cancer	5.09e-05	0.000449	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PRKACA—adrenal gland cancer	5.05e-05	0.000446	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MED12—adrenal gland cancer	5.04e-05	0.000445	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1R—adrenal gland cancer	4.97e-05	0.000438	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF2—adrenal gland cancer	4.92e-05	0.000434	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNAS—adrenal gland cancer	4.88e-05	0.00043	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1R—adrenal gland cancer	4.76e-05	0.00042	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	4.51e-05	0.000398	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	4.46e-05	0.000394	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MED12—adrenal gland cancer	4.39e-05	0.000388	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PRKACA—adrenal gland cancer	4.35e-05	0.000383	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—POMC—adrenal gland cancer	4.33e-05	0.000382	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—POMC—adrenal gland cancer	4.31e-05	0.00038	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—POMC—adrenal gland cancer	4.3e-05	0.000379	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TERT—adrenal gland cancer	4.28e-05	0.000377	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PRKACA—adrenal gland cancer	4.26e-05	0.000376	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—POMC—adrenal gland cancer	4.25e-05	0.000375	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PRKACA—adrenal gland cancer	4.24e-05	0.000374	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PRKACA—adrenal gland cancer	4.22e-05	0.000373	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EGFR—adrenal gland cancer	4.22e-05	0.000372	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PRKACA—adrenal gland cancer	4.18e-05	0.000369	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MED12—adrenal gland cancer	4.14e-05	0.000365	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MED12—adrenal gland cancer	4.1e-05	0.000362	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TERT—adrenal gland cancer	4.09e-05	0.000361	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNAS—adrenal gland cancer	4.09e-05	0.000361	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ABCB1—adrenal gland cancer	4.02e-05	0.000354	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—POMC—adrenal gland cancer	3.94e-05	0.000347	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—POMC—adrenal gland cancer	3.91e-05	0.000345	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—POMC—adrenal gland cancer	3.9e-05	0.000344	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—POMC—adrenal gland cancer	3.86e-05	0.000341	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—BAD—adrenal gland cancer	3.72e-05	0.000328	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PRKACA—adrenal gland cancer	3.68e-05	0.000325	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	3.67e-05	0.000324	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDC42—adrenal gland cancer	3.61e-05	0.000319	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	3.6e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDC42—adrenal gland cancer	3.59e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDC42—adrenal gland cancer	3.58e-05	0.000316	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—BAD—adrenal gland cancer	3.56e-05	0.000314	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDC42—adrenal gland cancer	3.55e-05	0.000313	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—adrenal gland cancer	3.55e-05	0.000313	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNAS—adrenal gland cancer	3.52e-05	0.000311	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF2—adrenal gland cancer	3.48e-05	0.000307	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF2—adrenal gland cancer	3.46e-05	0.000306	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ABCB1—adrenal gland cancer	3.46e-05	0.000305	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF2—adrenal gland cancer	3.45e-05	0.000305	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNAS—adrenal gland cancer	3.45e-05	0.000305	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNAS—adrenal gland cancer	3.43e-05	0.000303	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—adrenal gland cancer	3.43e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNAS—adrenal gland cancer	3.42e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF2—adrenal gland cancer	3.42e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNAS—adrenal gland cancer	3.39e-05	0.000299	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—BRAF—adrenal gland cancer	3.39e-05	0.000299	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1R—adrenal gland cancer	3.37e-05	0.000297	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1R—adrenal gland cancer	3.35e-05	0.000295	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1R—adrenal gland cancer	3.34e-05	0.000295	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1R—adrenal gland cancer	3.31e-05	0.000292	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—adrenal gland cancer	3.28e-05	0.00029	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EGFR—adrenal gland cancer	3.28e-05	0.00029	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—BRAF—adrenal gland cancer	3.24e-05	0.000286	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PRKACA—adrenal gland cancer	3.21e-05	0.000283	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EGFR—adrenal gland cancer	3.14e-05	0.000277	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	3.02e-05	0.000266	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	2.99e-05	0.000264	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNAS—adrenal gland cancer	2.98e-05	0.000263	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	2.93e-05	0.000258	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ABCB1—adrenal gland cancer	2.93e-05	0.000258	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TERT—adrenal gland cancer	2.9e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TERT—adrenal gland cancer	2.88e-05	0.000254	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TERT—adrenal gland cancer	2.87e-05	0.000254	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TERT—adrenal gland cancer	2.85e-05	0.000251	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—adrenal gland cancer	2.76e-05	0.000243	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNAS—adrenal gland cancer	2.6e-05	0.000229	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BAD—adrenal gland cancer	2.52e-05	0.000222	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BAD—adrenal gland cancer	2.51e-05	0.000221	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BAD—adrenal gland cancer	2.5e-05	0.000221	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BAD—adrenal gland cancer	2.48e-05	0.000218	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNAS—adrenal gland cancer	2.45e-05	0.000216	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CTNNB1—adrenal gland cancer	2.45e-05	0.000216	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNAS—adrenal gland cancer	2.43e-05	0.000214	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	2.4e-05	0.000212	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	2.38e-05	0.00021	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—adrenal gland cancer	2.37e-05	0.000209	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CTNNB1—adrenal gland cancer	2.34e-05	0.000207	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—adrenal gland cancer	2.32e-05	0.000205	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—adrenal gland cancer	2.31e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—adrenal gland cancer	2.3e-05	0.000203	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—adrenal gland cancer	2.3e-05	0.000202	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—adrenal gland cancer	2.28e-05	0.000201	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—adrenal gland cancer	2.28e-05	0.000201	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—adrenal gland cancer	2.28e-05	0.000201	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—adrenal gland cancer	2.25e-05	0.000199	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—adrenal gland cancer	2.23e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—adrenal gland cancer	2.21e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—adrenal gland cancer	2.21e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—adrenal gland cancer	2.2e-05	0.000194	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—adrenal gland cancer	2.18e-05	0.000193	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—adrenal gland cancer	2.01e-05	0.000177	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—adrenal gland cancer	1.94e-05	0.000171	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—adrenal gland cancer	1.89e-05	0.000167	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—adrenal gland cancer	1.86e-05	0.000164	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—adrenal gland cancer	1.75e-05	0.000154	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—adrenal gland cancer	1.66e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—adrenal gland cancer	1.65e-05	0.000146	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—adrenal gland cancer	1.65e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—adrenal gland cancer	1.65e-05	0.000145	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—adrenal gland cancer	1.63e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.63e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—adrenal gland cancer	1.63e-05	0.000144	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—adrenal gland cancer	1.6e-05	0.000141	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—adrenal gland cancer	1.56e-05	0.000138	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—adrenal gland cancer	1.4e-05	0.000123	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	1.31e-05	0.000116	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—adrenal gland cancer	1.31e-05	0.000116	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—adrenal gland cancer	1.31e-05	0.000115	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	1.3e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—adrenal gland cancer	1.3e-05	0.000115	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—adrenal gland cancer	1.29e-05	0.000114	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—adrenal gland cancer	1.1e-05	9.74e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—adrenal gland cancer	1.1e-05	9.68e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—adrenal gland cancer	1.09e-05	9.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—adrenal gland cancer	1.08e-05	9.56e-05	CbGpPWpGaD
